Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (131-140 of 169) with videos related to

Pageof 17
Sort By:
The Pediatric Infectious Disease Journal|October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve ChildrenCarine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
The New England Journal of Medicine|June 23, 2021
SARS-CoV-2 Variants and VaccinesPhilip R Krause, Thomas R Fleming, Ira M Longini, et al.
The Lancet. Infectious Diseases|February 22, 2015
Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trialMainga Hamaluba, Rama Kandasamy, Shyam R Upreti, et al.
Pediatric Diabetes|June 14, 2019
Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first resultsChristiane Winkler, Florian Haupt, Martin Heigermoser, et al.
Vaccine|August 31, 2011
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccinesNick J Andrews, Woolf T Walker, Adam Finn, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
Nature Medicine|October 13, 2022
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infectionAlexander J Mentzer, Daniel O'Connor, Sagida Bibi, et al.
Archives of Disease in Childhood|July 20, 2022
Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021Helen Ratcliffe, K S Tiley, Nick Andrews, et al.
Lancet (London, England)|November 14, 2021
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialRajeka Lazarus, Sarah Baos, Heike Cappel-Porter, et al.
Pageof 17

Showing results (131-140 of 169) with videos related to

Sort By:
Pageof 17
The Pediatric Infectious Disease Journal|October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve ChildrenCarine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
The New England Journal of Medicine|June 23, 2021
SARS-CoV-2 Variants and VaccinesPhilip R Krause, Thomas R Fleming, Ira M Longini, et al.
The Lancet. Infectious Diseases|February 22, 2015
Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trialMainga Hamaluba, Rama Kandasamy, Shyam R Upreti, et al.
Pediatric Diabetes|June 14, 2019
Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials-GPPAD-02 study design and first resultsChristiane Winkler, Florian Haupt, Martin Heigermoser, et al.
Vaccine|August 31, 2011
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccinesNick J Andrews, Woolf T Walker, Adam Finn, et al.
The Journal of Infection|February 25, 2015
Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategyCatherine A Jeppesen, Matthew D Snape, Hannah Robinson, et al.
Lancet (London, England)|June 12, 2022
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trialGrace Li, Federica Cappuccini, Natalie G Marchevsky, et al.
Nature Medicine|October 13, 2022
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infectionAlexander J Mentzer, Daniel O'Connor, Sagida Bibi, et al.
Archives of Disease in Childhood|July 20, 2022
Community seroprevalence of SARS-CoV-2 in children and adolescents in England, 2019-2021Helen Ratcliffe, K S Tiley, Nick Andrews, et al.
Lancet (London, England)|November 14, 2021
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialRajeka Lazarus, Sarah Baos, Heike Cappel-Porter, et al.
Pageof 17